Hot Features
Registrieren Sie sich kostenlos, um Echtzeitkurse, interaktive Charts, Live-Optionsfluss und mehr zu erhalten.
Zymeworks Announces Participation in Upcoming Investor Conferences VANCOUVER, British Columbia, Nov. 21, 2024 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology...
FDA Grants U.S. Approval of Ziihera® (zanidatamab-hrii) for the Treatment of Adults with Previously Treated, Unresectable or Metastatic HER2-positive (IHC 3+) Biliary Tract Cancer (BTC) Ziihera is...
Zymeworks Announces First Patient Dosed in Phase 1 Clinical Trial Evaluating ZW191 in Folate Receptor-⍺ Expressing Advanced Solid Tumors Global Phase 1 clinical trial will evaluate the safety and...
Zymeworks Announces Participation in Upcoming Investor Conferences VANCOUVER, British Columbia, Oct. 29, 2024 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology...
Zymeworks Presents New Preclinical Data on Antibody-Drug Conjugate Programs at EORTC-NCI-AACR Conference Presentations highlight key preclinical data that support investigational new drug...
Zymeworks Announces First Patient Dosed in Phase 1 Clinical Trial Evaluating ZW171 in Advanced Mesothelin-Expressing Cancers Global Phase 1 clinical trial will evaluate the safety and tolerability...
Zymeworks to Present Preclinical Data on Antibody-Drug Conjugate Programs at EORTC-NCI-AACR Conference Presentations to highlight progress in development of IND candidates ZW220 and ZW251 based on...
Zymeworks Announces Participation in Upcoming Investor Conferences VANCOUVER, British Columbia, Aug. 22, 2024 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology...
Zymeworks Announces Share Repurchase Program of up to $60 Million of its Common Stock Zymeworks intends to commence the Share Repurchase Program with $30.0 million in initial repurchases...
Zymeworks Appoints Leone Patterson as Chief Business and Financial Officer VANCOUVER, British Columbia, July 25, 2024 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage...
| Zeitraum † | Änderung | Änderung % | Handelsbeginn | Hoch | Niedrig | Durchsch. Volumen | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | -1 | -7.35294117647 | 13.6 | 13.6 | 12.3 | 211 | 13.4306962 | DE |
| 4 | -3.6 | -22.2222222222 | 16.2 | 16.3 | 12.3 | 343 | 14.02088072 | DE |
| 12 | 1.1 | 9.5652173913 | 11.5 | 16.3 | 11.1 | 333 | 13.56428469 | DE |
| 26 | 4.1 | 48.2352941176 | 8.5 | 16.3 | 7.75 | 466 | 10.87333724 | DE |
| 52 | 4.114 | 48.4798491633 | 8.486 | 16.3 | 7.75 | 466 | 10.10740709 | DE |
| 156 | 5.836 | 86.2803075103 | 6.764 | 16.3 | 5.876 | 521 | 9.25633381 | DE |
| 260 | 5.836 | 86.2803075103 | 6.764 | 16.3 | 5.876 | 521 | 9.25633381 | DE |
| Keine Diskussionen Gefunden. |
| Neuen Thread Erstellen |
Support: +44 (0) 203 8794 460 | support@advfn.de
Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen
Premium
